Global Mononucleosis Diagnostic Market, By Test Type (Epstein Barr Virus (EBV) Antibody Test, Monospot Test, Complete Blood Count Test), End-User (Hospitals, Laboratories, Others) – Industry Trends and Forecast to 2029.
Mononucleosis Diagnostic Market Analysis and Size
According to the Centers for Disease Control and Prevention, there were approximately 23,780 incident cases of infectious mononucleosis (IM) between 2002 and 2018, for an overall incidence rate of 104.2 cases per 100,000 person-years (p-yrs). The prevalence of IM diagnoses was highest among the youngest age groups and decreased with age. When compared to other race/ethnicity groups, non-Hispanic white service members had a higher incidence rate of IM diagnoses (123.4 per 100,000 p-yrs). The incidence of IM diagnoses among recruits was 3.4 times that of other enlisted personnel (106.0 per 100,000 p-yrs) and 5.6 times that of officers (64.7 per 100,000 p-yrs). As a result of rising incidences of infectious mononucleosis (IM), the demand for its diagnosis rises, resulting in growth.
Data Bridge Market Research analyses that the mononucleosis diagnostic market which is expected to reach at a CAGR of 5.00% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Mononucleosis Diagnostic Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test Type (Epstein Barr Virus (EBV) Antibody Test, Monospot Test, Complete Blood Count Test), End-User (Hospitals, Laboratories, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.), DiaSorin Molecular LLC (U.S.), Beckman Coulter, Inc. (U.S.), bioMérieux (France), Siemens (Germany), Sekisui Diagnostics (U.S.), ELITechGroup (France), Cardinal Health (U.S.), Immunostics Inc. (U.S.), Meridian Bioscience (U.S.), Thermo Fischer Scientific Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Mononucleosis is an infectious disease caused by epstein barr virus that spreads through saliva. Early diagnosis allows for effective treatment of the infection, necessitating the need for mononucleosis diagnostics. The benefits of mononucleosis diagnostics, such as precise diagnosis, perfect detection, and accurate results, may lead to good growth opportunities. All of these factors may bode well for the growth of the mononucleosis diagnostic market.
Global Mononucleosis Diagnostic Market Dynamics
Drivers
- Technological advancements act as a promising driver
Various novel technological advancements are occurring that can diagnose the infection faster than available on the market. For instance, Roche announced in 2020 that the USFDA had approved the Cobas EBV test, the first in-vitro quantitative diagnostic test in the US for the diagnosis of EBV Epstein-Barr Virus. This is a huge success for the healthcare industry and professionals because it will make it much easier to monitor patients who are at risk from this virus because it will perform a large number of tests in a short period of time.
- Increasing adolescent population is laying the foundation for expansion
Increasing adolescent population globally is also one of the major factor leading to growth of the market as mononucleosis is most common among teens and adults. More than half of all adolescents globally live in Asia. South Asia has nearly 350 million adolescents than any other region. It is followed by East Asia and the Pacific with over 300 million. The adolescent population of either of these regions dwarfs that of any other region in the world. According to World Health Organization (WHO) report, there are nearly 1.2 billion adolescents (10-19 years old) worldwide. In some countries, adolescents account for a quarter of the population and the number of adolescents is expected to rise through 2050, mainly in low- and middle-income countries (LMICs) where close to 90% of 10- to 19-year-olds live.
Opportunities
- Rising incidence of infectious mononucleosis is propelling growth
The rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research and development activities for IM diagnosis and treatment are the major factors that are increasing the global mononucleosis diagnostic market.
Restraints/Challenges
- High cost of mononucleosis diagnostic will challenge the market
High cost of mononucleosis diagnostic and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. There are some limitations associated with mononucleosis diagnostic tests which are expected to hamper the market's growth during the forecast period. There are only three tests that can diagnose mononucleosis and that is very low in regard to the rate by which the infectious mononucleosis is growing.
This mononucleosis diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mononucleosis diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In September 2019, Roche has launched two tests for use on the automated cobas 6800/8800 Systems in countries where the CE mark is accepted. The cobas EBV (Epstein-Barr virus) and cobas BKV (BK virus) Tests provide clinical decision-making with reliable, standardised, high-quality results to help manage the risk of infection and improve the management of severely immunocompromised transplant patients.
- In July 2019, NeuMoDx Molecular, a sample-to-result molecular diagnostics company focusing on central laboratory customers, has introduced CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), both of which can cause infectious mononucleosis and other illnesses.
Global Mononucleosis Diagnostic Market Scope
The mononucleosis diagnostic market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Test Type
- Epstein Barr Virus (EBV) Antibody Test
- Monospot Test
- Complete Blood Count Test
End-User
- Hospitals
- Laboratories
- Others
Mononucleosis Diagnostic Market Regional Analysis/Insights
The mononucleosis diagnostic market is analysed and market size insights and trends are provided by country, test type and end-user as referenced above.
The countries covered in the mononucleosis diagnostic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the mononucleosis diagnostic market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region, owing to rising incidence rate of infectious mononucleosis (IM), advancement in healthcare infrastructure supporting novel testing, and increasing research and development activities by major players in this region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising adolescent population and rising incidence of infectious mononucleosis (IM) in the region, owing to the rising adolescent population in this region. According to the UNICEF data, over half of all adolescents across the world live in Asia, and South Asia is home to the largest number of adolescents in any region in the world.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The mononucleosis diagnostic market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mononucleosis diagnostic market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mononucleosis diagnostic market. The data is available for historic period 2010-2020.
Competitive Landscape and Mononucleosis Diagnostic Market Share Analysis
The mononucleosis diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mononucleosis diagnostic market.
Some of the major players operating in the mononucleosis diagnostic market are:
- Abbott (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Weizmann Institute of Science (Israel)
- Biotest AG (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Genzyme (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Johnson & Johnson Services, Inc. (U.S.)
- BD (U.S.)
- DiaSorin Molecular LLC (U.S.)
- Beckman Coulter, Inc. (U.S.)
- bioMérieux (France)
- Siemens (Germany)
- Sekisui Diagnostics (U.S.)
- ELITechGroup (France)
- Cardinal Health (U.S.)
- Immunostics Inc. (U.S.)
- Meridian Bioscience (U.S.)
- Thermo Fischer Scientific Inc. (U.S.)
SKU-